Literature DB >> 33864226

Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images.

M F Santarelli1,2, D Genovesi3, M Scipioni4,5, V Positano3, B Favilli3, A Giorgetti3, G Vergaro6, L Landini3,7, M Emdin3,6, P Marzullo3.   

Abstract

OBJECTIVE: To evaluate the feasibility of kinetic modeling-based approaches from [18F]-Flobetaben dynamic PET images as a non-invasive diagnostic method for cardiac amyloidosis (CA) and to identify the two AL- and ATTR-subtypes. METHODS AND
RESULTS: Twenty-one patients with diagnoses of CA (11 patients with AL-subtype and 10 patients with ATTR-subtype of CA) and 15 Control patients with no-CA conditions underwent PET/CT imaging after [18F]Florbetaben bolus injection. A two-tissue-compartment (2TC) kinetic model was fitted to time-activity curves (TAC) obtained from left ventricle wall and left atrium cavity ROIs to estimate kinetic micro- and macro-parameters. Combinations of kinetic parameters were evaluated with the purpose of distinguishing Control subjects and CA patients, and to correctly label the last ones as AL- or ATTR-subtype. Resulting sensitivity, specificity, and accuracy for Control subjects were: 0.87, 0.9, 0.89; as far as CA patients, the sensitivity, specificity, and accuracy were respectively 0.9, 1, and 0.97 for AL-CA patients and 0.9, 0.92, 0.97 for ATTR-CA patients.
CONCLUSION: Pharmacokinetic analysis based on a 2TC model allows cardiac amyloidosis characterization from dynamic [18F]Florbetaben PET images. Estimated model parameters allows to not only distinguish between Control subjects and patients, but also between AL- and ATTR-amyloid patients.
© 2021. American Society of Nuclear Cardiology.

Entities:  

Keywords:  PET dynamic imaging; amyloid light chain (AL); amyloid transthyretin (ATTR); cardiac amyloidosis; kinetic parameters

Mesh:

Substances:

Year:  2021        PMID: 33864226     DOI: 10.1007/s12350-021-02608-8

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  19 in total

Review 1.  Systemic immunoglobulin light chain amyloidosis.

Authors:  Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz
Journal:  Nat Rev Dis Primers       Date:  2018-10-25       Impact factor: 52.329

2.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Stefan O Schonland; Efstathios Kastritis; Julian D Gillmore; Meletios A Dimopoulos; Thirusha Lane; Andrea Foli; Darren Foard; Paolo Milani; Lisa Rannigan; Ute Hegenbart; Philip N Hawkins; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood       Date:  2013-03-11       Impact factor: 22.113

Review 3.  Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions.

Authors:  Sukhdeep Bhogal; Vatsal Ladia; Puja Sitwala; Emilie Cook; Kailash Bajaj; Vijay Ramu; Carl J Lavie; Timir K Paul
Journal:  Curr Probl Cardiol       Date:  2017-04-13       Impact factor: 5.200

4.  Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis.

Authors:  Yong Joong Kim; Sejin Ha; Yong-Il Kim
Journal:  J Nucl Cardiol       Date:  2018-07-18       Impact factor: 5.952

5.  PET-CT evaluation of amyloid systemic involvement with [18F]-florbetaben in patient with proved cardiac amyloidosis: a case report.

Authors:  Dario Genovesi; Giuseppe Vergaro; Michele Emdin; Assuero Giorgetti; Paolo Marzullo
Journal:  J Nucl Cardiol       Date:  2017-03-21       Impact factor: 5.952

6.  Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy.

Authors:  Malte Kircher; Sandra Ihne; Joachim Brumberg; Caroline Morbach; Stefan Knop; K Martin Kortüm; Stefan Störk; Andreas K Buck; Theresa Reiter; Wolfgang R Bauer; Constantin Lapa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-23       Impact factor: 9.236

Review 7.  Novel pharmacotherapies for cardiac amyloidosis.

Authors:  Kevin M Alexander; Avinainder Singh; Rodney H Falk
Journal:  Pharmacol Ther       Date:  2017-06-22       Impact factor: 12.310

8.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Authors:  Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia
Journal:  Eur Heart J       Date:  2015-07-28       Impact factor: 29.983

9.  Cardiac amyloidosis detection by early bisphosphonate (99mTc-HMDP) scintigraphy.

Authors:  M F Santarelli; D Genovesi; V Positano; R Di Sarlo; M Scipioni; A Giorgetti; L Landini; P Marzullo
Journal:  J Nucl Cardiol       Date:  2020-06-28       Impact factor: 5.952

Review 10.  Contemporary Imaging Diagnosis of Cardiac Amyloidosis.

Authors:  Seung Pyo Lee; Jun Bean Park; Hyung Kwan Kim; Yong Jin Kim; Martha Grogan; Dae Won Sohn
Journal:  J Cardiovasc Imaging       Date:  2019-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.